Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225976 | 0.88 | KCNH2 (0.49) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5228111 | 0.86 | KCNH2 (0.53) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL508578 | 0.84 | KCNH2 (0.53) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5225028 | 0.84 | KCNH2 (0.51) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5228148 | 0.83 | KCNH2 (0.53) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5228883 | 0.83 | KCNH2 (0.53) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5227097 | 0.83 | KCNH2 (0.52) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL508951 | 0.82 | KCNH2 (0.51) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5229265 | 0.82 | KCNH2 (0.51) | KCNH2CYP3A4CYP2C9CYP2D6GRM5 | |
| SCHEMBL5225076 | 0.82 | KCNH2 (0.51) | KCNH2CYP3A4CYP2C9CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | KCNH2 3503/4885CYP3A4 47/4885CYP2C9 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.